Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Therapy vs Monotherapy for PAH in Systemic Sclerosis
NCT03053739Phase 4Unknown
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Dec 2016
- Primary completion
- Dec 2017
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in pulmonary arterial hypertension (PAH) and systemic sclerosis (SSc) comparing Combination arm A-Sildenafil and Bosentan with Monotherapy arm-Sildenafil and Placebo (2 arms). Primary endpoint: Change in Pulmonary Artery Pressures at 6 months. Status: unknown.
02
Drugs
bosentan
03
Conditions
pulmonary arterial hypertension (PAH)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT03053739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03053739.